Table 2.
Relapse-free period (Fine and Gray regression)
| N of events | Recurrence risk at 5 years (%) | SHR | 95% CI | p** | SHR* | 95% CI | p** | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Lower | Upper | Lower | Upper | |||||||
| HER2 | ||||||||||
| Negative: 0/1+ | 155 | 12 | 1 (Reference) | 1 (Reference) | ||||||
| 2+ | 32 | 12 | 1.06 | 0.76 | 1.47 | 0.747 | 0.95 | 0.67 | 1.35 | 0.790 |
| 3+ | 34 | 34 | 2.68 | 1.86 | 3.86 | <0.001 | 1.81 | 1.19 | 2.74 | 0.005 |
| PIK3CA | ||||||||||
| Negative | 103 | 17 | 1 (Reference) | 1 (Reference) | ||||||
| Positive | 42 | 16 | 0.98 | 0.71 | 1.35 | 0.892 | 1.00 | 0.72 | 1.41 | 0.987 |
* Adjusted for age, morphology, grade, hormone receptor status, tumour stage, type of breast surgery, type of axillary surgery, radiotherapy, endocrine therapy, chemotherapy
** p values in bold font indicate a statistically significant difference between the groups at the p level of <0.05